Streetbeat News

Products Services

AKYA

TMO

Akoya Biosciences, Inc. (AKYA) has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. (TMO) to market a spatial multiomics workflow. This collaboration combines Akoya's PhenoImager systems and PhenoCode reagents with Thermo Fisher's ViewRNA In Situ Hybridization Assays. The partnership aims to provide a comprehensive suite of multiomic solutions to enhance the understanding of tumor progression and biomarker development.

Portfolio Pulse from Charles Gross

January 07, 2024 | 4:05 pm

HEMP

During Dry January, the cannabis industry is offering alternatives to alcohol with new products. Cheech Marin and Tommy Chong have partnered with NorthEast Extracts LLC to launch their cannabis products in New York. BioWellnessX has introduced a premium THCa flower wholesale line. WhistlePig Whiskey has released a non-alcoholic, terpene-infused cocktail with proceeds benefiting Turning Tables. Illicit Gardens and Monopoly Melts have collaborated on Hash Holes, a series of craft pre-rolls. Hemp, Inc. is capitalizing on the demand for hemp-derived products, while Kiva Confections' Camino gummies offer a cost-effective and healthy alternative to cocktails.

Portfolio Pulse from Joana Scopel

January 07, 2024 | 3:53 pm

LCID

NIO

RIVN

TSLA

VWYAG

Argus analyst Bill Selesky maintains a bullish stance on Tesla, Inc. (NASDAQ:TSLA), predicting a 33% stock rally as he expects the company's growth to reaccelerate in 2024. Selesky cites Tesla's artificial intelligence in manufacturing and factory utilization as a significant competitive advantage. He also notes Tesla's current leadership in the EV market and potential for increased market share. Despite challenges faced by competitors like Ford (NYSE:F), General Motors (NYSE:GM), Toyota (NYSE:TM), Volkswagen (OTC:VWYAG), Nio (NYSE:NIO), Lucid Motors (NASDAQ:LCID), and Rivian (NASDAQ:RIVN), Tesla is poised for growth. Argus has set a $316 price target for Tesla stock.

Portfolio Pulse from Shanthi Rexaline

January 07, 2024 | 2:07 pm

BLK

BTCUSD

SHIBUSD

The first week of 2024 saw mixed expectations for a Bitcoin ETF approval by the SEC, with only 39% of financial advisors confident in an approval this year. BlackRock, VanEck, and Valkyrie Investments are awaiting the SEC's decision on their Bitcoin ETF applications. Economist Peter Schiff warned that the market might be disappointed by the outcome. Shiba Inu's burn rate surged by 373%, indicating a cautiously optimistic outlook for 2024. Crypto analysts highlighted the importance of Bitcoin and other cryptocurrencies like Solana and Ethereum, with the upcoming Bitcoin halving event also being a point of focus.

Portfolio Pulse from Benzinga Neuro

January 07, 2024 | 2:07 pm

AAPL

GOOG

GOOGL

MSFT

Apple Inc. (AAPL) had a significant week with opposition to UK surveillance laws, legal challenges, rumors of an early Vision Pro launch, and no new iPad in 2023. Apple, along with Alphabet Inc. (GOOG, GOOGL) and Microsoft Corp. (MSFT), opposed the UK's proposed surveillance laws through techUK. Apple's services business faces legal scrutiny, potentially affecting its revenue. The Vision Pro headset is rumored to launch in January, and new iPhones may have advanced cameras. The absence of a new iPad model breaks a 12-year tradition.

Portfolio Pulse from Benzinga Neuro

January 07, 2024 | 11:01 am

GOOG

GOOGL

IBM

The first week of 2024 brought significant updates in the AI space, including user feedback on Alphabet Inc.'s Google Bard, IBM's perspective on computer science degrees, and the potential for a premium Bard service. Additionally, AI was used to create a fake passport image and to bring Elvis Presley back to the stage. Alphabet Inc. is seeking user input to improve Google Bard, while IBM's Matthew Candy questions the necessity of computer science degrees due to AI advancements.

Portfolio Pulse from Benzinga Neuro

January 07, 2024 | 9:02 am

ATAI

CMPS

CYBN

DMTTF

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100 million in Series A funding to support FDA approval of MDMA for PTSD treatment. The company will rebrand as Lykos Therapeutics. The investment reflects growing interest in psychedelic treatments for mental illnesses. Atai Life Sciences, Compass Pathways, and Cybin Inc. are also advancing in the psychedelic space with significant investments and acquisitions.

Portfolio Pulse from Maureen Meehan

January 06, 2024 | 8:59 pm

ALK

Alaska Airlines has completed inspections on over 25% of its Boeing 737-9 fleet, with no concerning findings. The aircraft will be returned to service as inspections are finalized, ensuring full confidence in their safety.

Portfolio Pulse from Charles Gross

January 06, 2024 | 5:34 pm

FSR

KARS

RIVN

TSLA

Electric vehicle stocks fell in the week ending Jan. 5, with Tesla's Q4 deliveries exceeding expectations but not enough to lift the sector. Tesla lost its global EV leader status to BYD, faced a recall in China, and will provide 2024 guidance on Jan. 24. Rivian's Q4 deliveries slightly missed estimates, while Fisker adopted a dealer distribution model. Ford adjusted F-150 Lightning prices, and GM plans to compensate buyers for lost EV tax credits. The KraneShares Electric Vehicles ETF fell by 5.53% for the week.

Portfolio Pulse from Shanthi Rexaline

January 06, 2024 | 2:59 pm

AAPL

ANF

IBM

NVDA

Barron's weekend stock picks include Abercrombie & Fitch, Apple, Nvidia, and IBM. Abercrombie & Fitch's future growth is uncertain despite a recent spike. Apple faces a 5.9% YTD decline amid antitrust concerns. Shipping stocks like Maersk may benefit from Middle East conflict and Panama Canal drought. Nvidia is projected to generate $100 billion in free cash flow from AI chip sales. IBM's AI ambitions are met with skepticism from analysts.

Portfolio Pulse from Justin Chan

January 06, 2024 | 2:12 pm